Friday, January 28, 2022 2:57:08 AM
I noticed they have a decent amount of cash on the balance sheet. My guess is that they will need to hire additional sales people once the FDA clearance happens. IMO, the security trades like the company is private, so whether the company is on a $35mio market capitalization or lower really does not tell the true value. The company has been around for decades and has withstood the the changes in reimbursement and shortages of radioisotopes from a decade ago. It's interesting that the company is now entering the PET/CT market, to target Oncology which in my opinion is the game changer. Massive market, with reimbursement coverage. If the company gets the correct IR/PR we should see a higher value, perhaps your $15.00 price target. So, with the share count being correct that would make it a $400mil company. This year should be the make or break, clear the FDA hurdle, get a few sales of the new product, service revs for recurring income and some market participants the price action should follow.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM